Document is current
Any future updates will be listed below
-
Authors
Wang, Jiarou
Li, Linlin
Chen, Jingci
Wang, Rongxi
Xiang, Jialin
Peng, Xingtong
Wang, Yanwei
Luo, Yaping
Zhu, Lin
Kung, Hank F.
Zhou, Zhien
Xiao, Yu
Zhu, Zhaohui https://orcid.org/0009-0008-7394-9889
-
Funding
Funding for this research was provided by:
Chinese Academy of Medical Science Innovation Fund for Medical Sciences (2021-I2M-1-016)
National High-Level Hospital Clinical Research Funding (2022-PUMCH-C-004)
National High-Level Hospital Clinical Research Funding (2022-PUMCH-D-002)
National Natural Science Foundation of China (82272046)
- License Information
-
More Information
Article History
Received: 18 September 2025
Accepted: 14 November 2025
First Online: 10 December 2025
Declarations
:
: This study approved by the Institutional Review Board of Peking Union Medical College Hospital (No. ZS-2461).
: Informed consent was obtained from all individual participants included in the study.
: All participants provided written informed consent for the publication of the data collected in this study.
: Hank F. Kung is the founder of Five Eleven Pharma, which holds the patent rights for P16-093 and related technology. Prof. Kung was not involved in the collection, analysis, or interpretation of the data. Other authors have no conflicts of interest or relevant financial activities to disclose.
